Focused On-demand Library for Palmitoyltransferase ZDHHC16

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Abl-philin 2; Zinc finger DHHC domain-containing protein 16

Alternative UPACC:

Q969W1; D3DR52; D3DR53; D3DR54; Q5JTG7; Q5JTH0; Q8N4Z6; Q8WY84; Q9BSV3


Palmitoyltransferase ZDHHC16, also known as Abl-philin 2, plays a crucial role in cellular processes through the palmitoylation of proteins such as PLN and ZDHHC6. This enzyme is pivotal in embryonic heart development, cardiac function, and eye development by modulating the phosphorylation and homooligomerization of PLN. Additionally, ZDHHC16 is involved in the quaternary assembly, localization, stability, and function of ZDHHC6, and it may play roles in DNA damage response and apoptosis regulation. Its function in the proliferation of neural stem cells through the FGF/ERK pathway underscores its importance in cellular signaling and development.

Therapeutic significance:

Understanding the role of Palmitoyltransferase ZDHHC16 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.